Vaikeahan näitä on amatöörin arvuutella, mutta jos ne nyt meinaa tuolla Englannissakin ruveta näitä pistämään testiksi, niin kyllä se turvallisuus ja teho on jo aika pitkälle todettu.
Just tänään allekirjoittivat sopimuksen yhteistyöstä, mistä hiljan puhuttiin.
MOSCOW (Reuters) - Britain's AstraZeneca and Russia's Gamaleya Institute, which developed the Sputnik V vaccine, will sign a memorandum of intent on cooperation on Monday, the Kremlin said.
Russia's RDIF sovereign wealth fund said this month AstraZeneca would start clinical trials to test a combination of its experimental COVID-19 vaccine with the Sputnik V shot to see if this can boost the efficacy of the British drugmaker's vaccine.
Höbläkin uutisoi.
Astra Zeneca i ryskt vaccinsamarbete
https://www.hbl.fi/artikel/astra-zeneca-i-ryskt-vaccinsamarbete/
Tässä kerrottu tästä, miksi. Ovat samankaltaisia rokotteita ja yhdistelemällä voidaan saada etua.
AstraZeneca have announced a clinical trial programme to assess safety and immunogenicity of a combination of AZD1222, developed by AstraZeneca and Oxford University, and Sputnik V, developed by Russian Gamaleya Research institute.
Dr Zoltán Kis, Research Associate at the Future Vaccine Manufacturing Hub, Imperial College London, said:
“Both the AstraZeneca/Oxford vaccine candidate and the Sputnik V vaccine are adenovirus vectored vaccines and both deliver genetic instructions for the cells of the body to produce the Spike protein of SARS-CoV-2. The AstraZeneca/Oxford vaccine candidate is based on a chimpanzee adenovirus and the Sputnik V vaccine is based on a human adenovirus, thus the vectors (or carriers) of these two vaccines are slightly different.
“The immune system of the human body can generate an immune response against the adenoviral vector itself, thus if a second dose of the same adenovirus vectored vaccine is delivered, the immune system could destroy the vector, before the payload of the vaccine is delivered, therefore reducing the efficacy of the second vaccine dose. On the other hand, if the vector of the second (booster) dose of the vaccine is different from the vector of the first (prime) dose, the immune system will be less likely to destroy the vector of the vaccine, thus the efficacy of the heterologous boosting vaccination could be increased, compared to the situation where both the prime and boost doses were of the same vector type. Therefore, the reason why heterologous boosting could increase vaccine efficacy, is that the (partial) destruction of the second vaccine dose by the immune system can be avoided and because both vaccines contain instructions for producing the same antigen.
“Furthermore, having the possibility of combining these two vaccine types would allow for greater flexibility in the vaccination programs. This could lead to greater accessibility to vaccines, thus increasing the rate and scale of Covid-19 vaccination coverage.
“For these reasons, the news regarding clinical trials of this heterologous boosting Covid-19 vaccination is a promising one.”
Prof Helen Fletcher, Professor of Immunology at the London School of Hygiene & Tropical Medicine, a vaccines expert and UKRI’s Director of International Development, said:
“This is the logical next step in vaccine development for COVID-19 as priming with one type of vaccine and boosting with another is a commonly used strategy for increasing the level and duration of efficacy against infectious disease. Combining vaccines has the potential to be more effective through boosting immune responses to a higher level and maintaining immunity over a longer period of time.
“The AZD1222 vaccine given alone would prime an immune response against spike protein – but also prime a response against the vaccine itself – giving AZD1222 a second time increases immune responses against spike protein but this increase is limited because our immune system recognises and neutralises some of the vaccine particles before they can express the spike protein. In a heterologous boost we would give spike protein using one vaccine platform and then present the same spike protein using a different vaccine platform – this could give a much stronger immune response to spike because the second vaccination isn’t limited by any anti-vector immune response.
“Combining AZD1222 with an mRNA vaccine would be a heterologous boost as the vaccine platforms are very different. Combining 2 different adenoviruses could be a heterologous boost if the two viral vectors are different enough to avoid anti-vector immunity. It would make sense in terms of vaccine distribution to use two adenovirus vaccines together so definitely worth testing.”
https://www.sciencemediacentre.org/...strazeneca-vaccine-and-the-sputnik-v-vaccine/
www.mtvuutiset.fi
